Doximity, Inc. (DOCS) is a publicly traded company in the Healthcare — Medical - Healthcare Information Services industry listed on NYSE. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Doximity, Inc. provides a digital platform, hosted in the cloud, specifically designed for healthcare practitioners throughout the United States. This platform delivers a suite of specialized tools, empowering its members to connect with peers, streamline patient treatment, conduct remote consultations, access current medical information and research, and advance their professional careers.
Is Doximity, Inc. stock overvalued or undervalued in 2026?
Doximity, Inc. (DOCS) trades at 40.3× earnings (P/E), above the median of the 246 healthcare companies over $2bn in Kaplio's universe. At its sector median (30.4×) $26 (-24 %).
Kaplio overview: Doximity, Inc.
Market cap $6B · 52 weeks $18 – $67 (49 % below the high) · P/E 40.3× · 2027 expected P/E 25.4× · Dividend none · Next earnings November 5, 2026 · expected EPS $0.35 · Closing price, Oct 28 · accounts published Aug 6.
- Valuation: P/E 40.3× (expensive).
- Business: ROIC 15 % (solid).
- Balance sheet: Net cash/EBITDA 0.8× (solid).
- Earnings: 6 of 8 (on track).
What would it be worth at its usual multiples?
At its sector median (30.4×) $26 (-24 %). Implied price from applying the reference multiples to today's earnings (or book value, or FFO) per share. Not a fair value: it is where the stock would trade at its usual multiples.
What matters in pharma: 7 of 7 pass
- R&D / Revenue 20.3 %, passes.
- 5y EPS growth 30.1 %, passes.
- Gross margin 89.1 %, passes.
- FCF / Net Income 161.9 %, passes.
- ROIC 15.3 %, passes.
- Net debt / EBITDA −0.8×, passes.
- P/E vs own 10y history 40.3×, passes.
Against its peers (reference peers) — Doximity, Inc.: P/E 40.3×; EV/EBITDA 24.1×; ROIC 15.3 %; $6.1B. HealthEquity, Inc. (P/E 36.6×; EV/EBITDA 18.3×; ROIC 8.6 %; $8.4B), The Cooper Companies, Inc. (P/E 20.3×; EV/EBITDA 15.0×; ROIC 4.8 %; $11.3B), Encompass Health Corporation (P/E 19.9×; EV/EBITDA 8.2×; ROIC 12.8 %; $12.0B).
Profitability
| Return on Equity | 16.95% |
| Return on Invested Capital | 15.31% |
| Return on Assets | 15.41% |
| Gross Margin | 88.07% |
| Operating Margin | 29.60% |
| Net Margin | 25.48% |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 6.08 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 17.11 |
Price Performance
| 1 month | +29.15% |
| 3 months | +63.80% |
| Year-to-date | -22.65% |
| 1 year | -48.70% |
| 3 years | +63.56% |
| 5 years | -50.71% |
Related companies: VTRS · COO · GH · ICLR · TEM · HQY · SOLV · EHC
Explore sector: Healthcare · Medical - Healthcare Information Services
More sections of DOCS: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks